NeuroStar TMS
Transcranial Magnetic Stimulation
NeuroStar Advanced Therapy
We now offer Transcranial Magnetic Stimulation (TMS) treatment for depression using NeuroStar Advanced Therapy, a cutting-edge, non-invasive approach to treat depression at the source - your brain!
TMS is:
-
Safe and FDA-cleared
-
Non-drug and non-invasive
-
Covered by most insurance plans
If you’ve felt like nothing else is working—or you’re simply ready for a new path forward—TMS could be the proactive next step.
​
Proven results:
83% of patients see improvement in depression symptoms
62% of patients experience symptom relief (remission)
​
Who is a good candidate for TMS?
TMS is often associated with treatment-resistant depression, but it doesn’t have to be your last resort! In fact, many individuals are now exploring TMS earlier in their treatment journey to avoid long-term medication use or worsening symptoms.
You may be a candidate if you:
-
Are age 15 or older and diagnosed with Major Depressive Disorder
-
Have tried at least one antidepressant without success
-
Want a non-drug option that works alongside therapy and other treatments
TMS can also be used as an adjunct treatment for Obsessive-Compulsive Disorder (OCD) in adults.
​
The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adults and adolescents (15 and older) suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.
The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
NeuroStar Advanced Therapy is only available by prescription. A doctor or nurse practitioner can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.
Visit neurostar.com for full safety and prescribing information.
*Outcomes Registry data was published by Sackeim HA, et al. J Affective Disorders, 2020, 277(12):65-74. The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score <=3 and “complete remission” was defined as a CGI-S score <=2 at the end of treatment.